FDA grants Fast Track Designation to Selinexor for the Treatment of Myelofibrosis

“Fast Track Designation for selinexor highlights its potential to address the unmet medical need in myelofibrosis, an important acknowledgement as we continue our pivotal Phase 3 study,” said Reshma Rangwala, MD, PhD, Chief Medical Officer of Karyopharm. “Selinexor’s unique mechanism of action, XPO1 inhibition, is a novel and potentially fundamental mechanism in myelofibrosis. We have been highly encouraged by the efficacy and safety data observed to date [in our Phase 1 study] with selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis and believe selinexor has the potential to shift the treatment paradigm. We look forward to continued interaction with the FDA as we advance the development of this promising treatment for patients in need.”

Share:

More News

“Based on the results from these two independent studies, we have identified patient populations showing improved progression-free survival, highlighting the potential of samuraciclib in combination with SERDs as an effective new treatment option for these patients. Carrick is further validating these two selection strategies in two additional Phase 2 studies

Soo-Jung Kim, Head of New Drug Development at Hyundai ADM, added: “Our AACR announcement highlighted that Penetrium™’s potential as a gateway therapy in the era of democratized immunotherapy. With major patent expirations approaching, we are advancing our development strategy to secure global leadership in combination immunotherapy.”

CNS CEO John Climaco stated, “The successful transfer of the Orphan Drug Designations for TPI 287 demonstrates our operational efficiency as well as our ongoing commitment to the development of neuro oncology-focused, cutting-edge chemotherapies. As we prepare to commence patient enrollment for a Phase 2 study around year-end 2025, this

“This clinical trial and the FDA clearance represents a pivotal milestone in our mission to develop precise, data-driven cancer therapies for patients with limited treatment options,” said Panna Sharma, President and CEO of Lantern Pharma. “The STK11 and KEAP1 mutant NSCLC population represents an important market opportunity and, a group